Navigation Links
Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
Date:9/17/2009

BASKING RIDGE, N.J., Sept. 17 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that the European Patent Office (EPO) has notified the Company of its intent to grant a patent with claims directed to oligonucleotide modulators of blood coagulation factor aptamers in EP 1401853. This new patent grant in the Company's portfolio extends the scope and breadth of Regado's intellectual property estate.

"We are very pleased with the EPO's decision to grant claims from a patent we believe will be fundamental to the development of active control agents for therapeutic aptamers," said David J. Mazzo, Ph.D., President and Chief Executive Officer of Regado Biosciences, Inc. "This patent is key to the protection of the Company's lead product candidate, the REG1 anticoagulation system, and its grant enables the exclusive use of modulator technology in this field solely by Regado."

The allowed claims in EP1401853 broadly cover oligonucleotide modulators that hybridize under physiological conditions to a blood coagulation factor aptamer, and, in so doing, specifically and rapidly reverse the anticoagulant and antithrombotic effects of the aptamer. Upon completion of certain formalities, the patent should issue in approximately six months. Regado also controls certain U.S. patent applications and issued patents covering aspects of the REG1 system, including patents covering certain RNA aptamers to coagulation factors (e.g. US7,312,325) and aptamer modulation (e.g. US7,300,922) exclusively licensed from Duke University, as well as improved coagulation factor modulator systems (e.g., US7,304,041) owned by the Company.

ABOUT REGADO BIOSCIENCES

Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.

ABOUT REG1 and REG2

Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006. REG1 is intended for application in arterial thrombosis applications, initially in Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention. REG2, Regado's second product candidate, consists of a subcutaneously administered formulation of RB006 paired with the IV bolus formulation of RB007. REG2 is intended for use in venous thrombosis indications

ABOUT APTAMERS

RB006 is a member of a class of compounds called aptamers. Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein. A key unique feature of aptamers derives from the fact that they are formed from nucleic acids. As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing it biologic effects.

More information can be found at http://www.regadobio.com.


'/>"/>
SOURCE Regado Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
2. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
3. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
4. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
5. Regado Biosciences Expands Medical Advisory Board
6. Regado Biosciences Establishes Medical Advisory Board
7. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
8. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
9. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
10. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
11. David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... According to a new market research report "Oligonucleotide Synthesis Market ... (Research, PCR, Gene, DNA, NGS, Diagnostic, RNAI), End user (Academic, Pharmaceutical, ... is expected to reach USD 2.20 Billion by 2021 from USD ... forecast period. Continue Reading ... ...
(Date:12/8/2016)... ... 2016 , ... From wearable devices that can improve performance ... Thursday, December 15th a panel of entrepreneurs, innovators and a Philadelphia Eagles front ... Smart Talk session. Smart Talk will run from 8:30 – 10:30 a.m. at ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... — optogenetics — is key to exciting advances in the study and mapping ... light projected via free-space optics stimulates small, transparent organisms and excites neurons within ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc ... to client demand KbioBox developed a sophisticated “3 click” gene dditing off target ... from KBioBox’s new website, https://www.kbiobox.com/ and powered by the company’s ...
Breaking Biology Technology:
(Date:12/7/2016)... , Dec. 7, 2016   Veridium , ... the appointment of new CEO James Stickland ... with decades of experience, has served in senior ... where he specialized in expanding a pipeline of ... portfolios. He most recently served as managing director ...
(Date:12/5/2016)... , Dec. 5, 2016  The Office of ... published "Can CT Scans Enhance or Replace Medico ... potential of supporting or replacing forensic autopsies with ... scan. In response to recommendations made ... exploring using CT scans as a potential component ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH ... new partnership initiative targeting national brands, industry thought-leaders ... reward their respective audiences for taking steps to ... its inception in 2012, higi has built the ... impacting over 38 million people who have conducted ...
Breaking Biology News(10 mins):